Open AccessA multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Author(s) -
Kumar Prabhash,
D.C. Doval,
Bharath Rangarajan,
Naresh Somani,
Aarohan Pruthi,
Yulia Dyachkova,
Tarun Puri
Publication year - 2021
Publication title -
cancer research statistics and treatment
Language(s) - English
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_159_21
Subject(s) - docetaxel , ramucirumab , medicine , taxane , neutropenia , oncology , lung cancer , paclitaxel , chemotherapy , randomized controlled trial , surgery , cancer , breast cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom